NASDAQ:MGNX - MacroGenics Stock Price, Price Target & More

$23.04 +0.06 (+0.26 %)
(As of 04/26/2018 03:20 AM ET)
Previous Close$23.04
Today's Range$22.23 - $23.47
52-Week Range$14.36 - $32.74
Volume207,283 shs
Average Volume360,385 shs
Market Capitalization$975.61 million
P/E Ratio-42.67
Dividend YieldN/A
Beta2.46

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Debt-to-Equity RatioN/A
Current Ratio6.48%
Quick Ratio6.48%

Price-To-Earnings

Trailing P/E Ratio-42.67
Forward P/E Ratio-5.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$157.74 million
Price / Sales6.14
Cash FlowN/A
Price / CashN/A
Book Value$8.13 per share
Price / Book2.83

Profitability

EPS (Most Recent Fiscal Year)($0.54)
Net Income$-19,620,000.00
Net Margins-12.44%
Return on Equity-8.22%
Return on Assets-6.74%

Miscellaneous

Employees330
Outstanding Shares42,030,000

How to Become a New Pot Stock Millionaire

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics (NASDAQ:MGNX) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.58 by $0.22. The biopharmaceutical company earned $152.36 million during the quarter, compared to the consensus estimate of $152.59 million. MacroGenics had a negative net margin of 12.44% and a negative return on equity of 8.22%. View MacroGenics' Earnings History.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for MacroGenics.

What price target have analysts set for MGNX?

10 equities research analysts have issued 1 year target prices for MacroGenics' shares. Their predictions range from $22.00 to $44.00. On average, they anticipate MacroGenics' stock price to reach $31.8571 in the next twelve months. View Analyst Ratings for MacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a decrease in short interest in April. As of April 13th, there was short interest totalling 3,055,741 shares, a decrease of 24.3% from the March 30th total of 4,034,237 shares. Based on an average trading volume of 405,524 shares, the days-to-cover ratio is presently 7.5 days. Currently, 9.4% of the shares of the stock are sold short.

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:
  • Dr. Scott Koenig, Chief Exec. Officer, Pres and Director (Age 66)
  • Mr. James Karrels, Chief Financial Officer, Sr. VP and Sec. (Age 51)
  • Dr. Ezio Bonvini M.D., Chief Scientific Officer and Sr. VP of Research (Age 64)
  • Mr. Eric Blasius Risser, Chief Bus. Officer and Sr. VP of Bus. Devel. & Portfolio Management (Age 45)
  • Dr. Jon M. Wigginton M.D., Chief Medical Officer and Sr. VP of Clinical Devel. (Age 56)

Has MacroGenics been receiving favorable news coverage?

Media stories about MGNX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MacroGenics earned a news sentiment score of 0.25 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $23.04.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $975.61 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (MGNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  412
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MacroGenics (NASDAQ:MGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for MacroGenics in the last 12 months. Their average twelve-month price target is $31.8571, suggesting that the stock has a possible upside of 38.27%. The high price target for MGNX is $44.00 and the low price target for MGNX is $22.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.782.822.82
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.8571$31.1250$31.8889$31.5556
Price Target Upside: 38.27% upside1.91% downside37.27% upside66.08% upside

MacroGenics (NASDAQ:MGNX) Consensus Price Target History

Price Target History for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/14/2018Morgan StanleyReiterated RatingEqual Weight -> Equal Weight$18.00 -> $26.00MediumView Rating Details
3/5/2018HC WainwrightInitiated CoverageBuy -> Buy$38.00HighView Rating Details
1/24/2018CowenReiterated RatingBuyLowView Rating Details
1/23/2018SunTrust BanksReiterated RatingBuy$31.00HighView Rating Details
1/23/2018BTIG ResearchReiterated RatingBuy$28.00HighView Rating Details
12/11/2017Raymond JamesReiterated RatingBuyMediumView Rating Details
11/10/2017CitigroupBoost Price TargetNeutral$18.00 -> $22.00N/AView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$34.00HighView Rating Details
9/11/2017WedbushReiterated RatingOutperform$44.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
6/14/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

MacroGenics (NASDAQ:MGNX) Earnings History and Estimates Chart

Earnings by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($4.72)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.13)($1.02)($1.08)
Q2 20182($1.29)($1.18)($1.24)
Q3 20183($1.33)($1.10)($1.22)
Q4 20183($1.29)($1.13)($1.19)

MacroGenics (NASDAQ MGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($1.11)N/AView Earnings Details
2/27/2018Q4 2017$2.58$2.80$152.59 million$152.36 millionViewN/AView Earnings Details
11/8/2017Q3 2017($1.09)($1.28)$5.50 million$1.70 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.05)($1.14)$15.82 million$1.70 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.56)($0.89)$12.36 million$8.18 millionViewN/AView Earnings Details
11/4/2015Q3 2015($0.21)($0.46)$22.95 million$14.68 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01$19.67 million$20.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MacroGenics (NASDAQ:MGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MacroGenics (NASDAQ MGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.82%
Institutional Ownership Percentage: 80.19%
Insider Trading History for MacroGenics (NASDAQ:MGNX)
Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ MGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2018Eric Blasius RisserSVPSell1,000$31.08$31,080.0010,100View SEC Filing  
3/5/2018James KarrelsCFOSell5,000$31.00$155,000.00View SEC Filing  
3/2/2018Eric Blasius RisserSVPSell4,000$30.00$120,000.0013,100View SEC Filing  
2/28/2018Eric Blasius RisserSVPSell1,000$25.01$25,010.00View SEC Filing  
2/28/2018Lynn CilinskiVPSell23,967$25.01$599,414.67View SEC Filing  
1/24/2018Eric Blasius RisserSVPSell3,000$22.50$67,500.0012,100View SEC Filing  
1/17/2018Jon Marc WiggintonSVPSell5,000$20.00$100,000.00View SEC Filing  
11/21/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.0035,000View SEC Filing  
10/25/2017Jon Marc WiggintonSVPSell10,000$20.00$200,000.0040,000View SEC Filing  
6/5/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.0035,000View SEC Filing  
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.0045,000View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.0010,000View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.688,154View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.0020,000View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.005,000View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.8410,845View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.006,923View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.0059,435View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.001,923View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.4870,317View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.9373,434View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MacroGenics (NASDAQ MGNX) News Headlines

Source:
DateHeadline
MacroGenics (MGNX) Given Consensus Recommendation of "Hold" by BrokeragesMacroGenics (MGNX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 25 at 3:32 PM
MacroGenics (MGNX) to Release Quarterly Earnings on TuesdayMacroGenics (MGNX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 7:56 AM
MacroGenics (MGNX) Cut to "Sell" at ValuEngineMacroGenics (MGNX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 23 at 11:18 PM
MacroGenics (MGNX) Cut to Sell at Zacks Investment ResearchMacroGenics (MGNX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 19 at 5:18 PM
$7.46 Million in Sales Expected for MacroGenics Inc (MGNX) This Quarter$7.46 Million in Sales Expected for MacroGenics Inc (MGNX) This Quarter
www.americanbankingnews.com - April 19 at 3:04 AM
MacroGenics (MGNX) Upgraded to "Hold" at Zacks Investment ResearchMacroGenics (MGNX) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:49 PM
-$1.08 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter-$1.08 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter
www.americanbankingnews.com - April 17 at 1:17 PM
MacroGenics (MGNX) Downgraded by BidaskClubMacroGenics (MGNX) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 10:19 PM
MacroGenics (MGNX) Downgraded by ValuEngineMacroGenics (MGNX) Downgraded by ValuEngine
www.americanbankingnews.com - April 13 at 1:35 PM
MacroGenics (MGNX) Stock Rating Lowered by Zacks Investment ResearchMacroGenics (MGNX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:00 PM
Investor Expectations to Drive Momentum within Companhia de saneamento Basico Do Estado De Sao Paulo ...Investor Expectations to Drive Momentum within Companhia de saneamento Basico Do Estado De Sao Paulo ...
globenewswire.com - April 13 at 9:29 AM
Leerink Swann Reaffirms "Outperform" Rating for MacroGenics (MGNX)Leerink Swann Reaffirms "Outperform" Rating for MacroGenics (MGNX)
www.americanbankingnews.com - April 10 at 8:27 AM
MacroGenics (MGNX) Upgraded at Zacks Investment ResearchMacroGenics (MGNX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 7:17 PM
MacroGenics (MGNX) Cut to "Hold" at BidaskClubMacroGenics (MGNX) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
MacroGenics (MGNX) Stock Rating Reaffirmed by CowenMacroGenics (MGNX) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 4 at 9:36 PM
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to ...MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to ...
globenewswire.com - April 3 at 9:25 AM
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 2 at 4:43 PM
MacroGenics Inc (MGNX) Receives Average Recommendation of "Buy" from AnalystsMacroGenics Inc (MGNX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 31 at 3:50 PM
Zacks: Brokerages Expect MacroGenics Inc (MGNX) Will Announce Earnings of -$1.10 Per ShareZacks: Brokerages Expect MacroGenics Inc (MGNX) Will Announce Earnings of -$1.10 Per Share
www.americanbankingnews.com - March 31 at 3:14 PM
MacroGenics (MGNX) Stock Rating Upgraded by Zacks Investment ResearchMacroGenics (MGNX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:26 AM
MacroGenics (MGNX) Upgraded at TheStreetMacroGenics (MGNX) Upgraded at TheStreet
www.americanbankingnews.com - March 29 at 11:11 AM
What Should You Know About MacroGenics Inc’s (NASDAQ:MGNX) Growth?What Should You Know About MacroGenics Inc’s (NASDAQ:MGNX) Growth?
finance.yahoo.com - March 28 at 4:38 PM
MacroGenics Inc. (MGNX) Is Falling After Offering AnnouncementMacroGenics Inc. (MGNX) Is Falling After Offering Announcement
www.nasdaq.com - March 28 at 9:09 AM
Macrogenics (MGNX) Prices 4.5M Common Stock Offering at $21.25/ShareMacrogenics (MGNX) Prices 4.5M Common Stock Offering at $21.25/Share
www.streetinsider.com - March 28 at 9:09 AM
MacroGenics Announces Pricing of Public Offering of Common StockMacroGenics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 28 at 9:09 AM
MacroGenics (MGNX) Rating Reiterated by SunTrust BanksMacroGenics (MGNX) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 26 at 6:30 PM
MacroGenics Announces Proposed Public Offering of Common StockMacroGenics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 26 at 4:49 PM
 Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $7.46 Million Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $7.46 Million
www.americanbankingnews.com - March 16 at 4:40 AM
Eric Blasius Risser Sells 1,000 Shares of MacroGenics Inc (MGNX) StockEric Blasius Risser Sells 1,000 Shares of MacroGenics Inc (MGNX) Stock
www.americanbankingnews.com - March 14 at 8:29 PM
MacroGenics (MGNX) Price Target Increased to $26.00 by Analysts at Morgan StanleyMacroGenics (MGNX) Price Target Increased to $26.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:44 AM
MacroGenics Inc (MGNX) Expected to Post Earnings of -$1.10 Per ShareMacroGenics Inc (MGNX) Expected to Post Earnings of -$1.10 Per Share
www.americanbankingnews.com - March 14 at 11:26 AM
BidaskClub Upgrades MacroGenics (MGNX) to "Buy"BidaskClub Upgrades MacroGenics (MGNX) to "Buy"
www.americanbankingnews.com - March 10 at 11:34 PM
MacroGenics to Present at Cowen Health Care ConferenceMacroGenics to Present at Cowen Health Care Conference
finance.yahoo.com - March 9 at 10:58 AM
James Karrels Sells 5,000 Shares of MacroGenics Inc (MGNX) StockJames Karrels Sells 5,000 Shares of MacroGenics Inc (MGNX) Stock
www.americanbankingnews.com - March 8 at 12:31 AM
MacroGenics Inc (MGNX) SVP Sells $120,000.00 in StockMacroGenics Inc (MGNX) SVP Sells $120,000.00 in Stock
www.americanbankingnews.com - March 6 at 7:17 PM
MacroGenics Inc (MGNX) Given Consensus Rating of "Buy" by AnalystsMacroGenics Inc (MGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 6 at 3:45 PM
Prosight Management LP Purchases Shares of 607,696 MacroGenics Inc (MGNX)Prosight Management LP Purchases Shares of 607,696 MacroGenics Inc (MGNX)
www.americanbankingnews.com - March 5 at 2:54 PM
HC Wainwright Initiates Coverage on MacroGenics (MGNX)HC Wainwright Initiates Coverage on MacroGenics (MGNX)
www.americanbankingnews.com - March 5 at 11:49 AM
MacroGenics Inc (MGNX) Shares Sold by Citadel Advisors LLCMacroGenics Inc (MGNX) Shares Sold by Citadel Advisors LLC
www.americanbankingnews.com - March 5 at 6:43 AM
Wedbush Analysts Boost Earnings Estimates for MacroGenics Inc (MGNX)Wedbush Analysts Boost Earnings Estimates for MacroGenics Inc (MGNX)
www.americanbankingnews.com - March 5 at 2:06 AM
MacroGenics (MGNX) Raised to Hold at ValuEngineMacroGenics (MGNX) Raised to Hold at ValuEngine
www.americanbankingnews.com - March 4 at 2:22 PM
Brokers Offer Predictions for MacroGenics Incs FY2021 Earnings (MGNX)Brokers Offer Predictions for MacroGenics Inc's FY2021 Earnings (MGNX)
www.americanbankingnews.com - March 2 at 5:30 PM
MacroGenics Inc Expected to Post Q3 2018 Earnings of ($1.10) Per Share (MGNX)MacroGenics Inc Expected to Post Q3 2018 Earnings of ($1.10) Per Share (MGNX)
www.americanbankingnews.com - March 2 at 11:33 AM
MacroGenics Inc (MGNX) to Post Q1 2018 Earnings of ($1.13) Per Share, SunTrust Banks ForecastsMacroGenics Inc (MGNX) to Post Q1 2018 Earnings of ($1.13) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - March 2 at 8:42 AM
Insider Selling: MacroGenics Inc (MGNX) SVP Sells 1,000 Shares of StockInsider Selling: MacroGenics Inc (MGNX) SVP Sells 1,000 Shares of Stock
www.americanbankingnews.com - March 1 at 10:44 PM
Insider Selling: MacroGenics Inc (MGNX) VP Sells 23,967 Shares of StockInsider Selling: MacroGenics Inc (MGNX) VP Sells 23,967 Shares of Stock
www.americanbankingnews.com - March 1 at 9:32 PM
MacroGenics Inc (MGNX) Shares Sold by Spark Investment Management LLCMacroGenics Inc (MGNX) Shares Sold by Spark Investment Management LLC
www.americanbankingnews.com - February 28 at 5:44 PM
MacroGenics tops 4Q profit forecastsMacroGenics tops 4Q profit forecasts
finance.yahoo.com - February 28 at 9:44 AM
MacroGenics Provides Update on Corporate Progress and 2017 Financial ResultsMacroGenics Provides Update on Corporate Progress and 2017 Financial Results
finance.yahoo.com - February 27 at 4:46 PM
MacroGenics Inc (MGNX) Shares Bought by OppenheimerFunds Inc.MacroGenics Inc (MGNX) Shares Bought by OppenheimerFunds Inc.
www.americanbankingnews.com - February 25 at 1:20 PM

SEC Filings

MacroGenics (NASDAQ:MGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MacroGenics (NASDAQ:MGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MacroGenics (NASDAQ MGNX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.